Leuthold Group LLC Invests $1.86 Million in iShares Biotechnology ETF $IBB

Leuthold Group LLC acquired a new stake in iShares Biotechnology ETF (NASDAQ:IBB) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 12,903 shares of the financial services provider’s stock, valued at approximately $1,863,000.

Several other large investors have also bought and sold shares of IBB. Citigroup Inc. grew its position in shares of iShares Biotechnology ETF by 27.0% in the 2nd quarter. Citigroup Inc. now owns 4,073,967 shares of the financial services provider’s stock valued at $515,398,000 after buying an additional 865,823 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of iShares Biotechnology ETF by 74.2% during the second quarter. JPMorgan Chase & Co. now owns 833,196 shares of the financial services provider’s stock worth $105,408,000 after acquiring an additional 355,000 shares during the last quarter. Bronte Capital Management Pty Ltd. lifted its stake in shares of iShares Biotechnology ETF by 12.6% in the second quarter. Bronte Capital Management Pty Ltd. now owns 295,346 shares of the financial services provider’s stock worth $37,000 after acquiring an additional 32,947 shares during the period. Employees Retirement System of Texas bought a new stake in iShares Biotechnology ETF in the second quarter valued at approximately $25,049,000. Finally, Thrivent Financial for Lutherans increased its position in iShares Biotechnology ETF by 5.8% during the 3rd quarter. Thrivent Financial for Lutherans now owns 111,863 shares of the financial services provider’s stock valued at $16,149,000 after purchasing an additional 6,157 shares during the period. 62.45% of the stock is owned by institutional investors.

iShares Biotechnology ETF Stock Performance

iShares Biotechnology ETF stock opened at $170.64 on Friday. iShares Biotechnology ETF has a 52-week low of $107.43 and a 52-week high of $179.64. The firm has a 50 day moving average price of $171.65 and a two-hundred day moving average price of $156.97.

iShares Biotechnology ETF Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, December 19th. Investors of record on Tuesday, December 16th were paid a dividend of $0.1831 per share. This is a boost from iShares Biotechnology ETF’s previous quarterly dividend of $0.08. This represents a $0.73 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend was Tuesday, December 16th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.